Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company’s web site at www.chelseatherapeutics.com.
- 18 years ago
QualityStocks
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…